These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20018309)

  • 21. Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.
    Miller NL; Bissonette EA; Bahnson R; Wilson J; Theodorescu D
    Cancer; 2003 Mar; 97(5):1203-10. PubMed ID: 12599226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer.
    Martin T; Röddiger S; Kurek R; Dannenberg T; Eckart O; Kolotas C; Heyd R; Rogge B; Baltas D; Tunn U; Zamboglou N
    Radiother Oncol; 2004 Apr; 71(1):35-41. PubMed ID: 15066294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate].
    Boccon-Gibod L
    Prog Urol; 1997 Feb; 7(1):97-8. PubMed ID: 9116748
    [No Abstract]   [Full Text] [Related]  

  • 24. Cancer of the prostate. Mechanisms of action of antiandrogens.
    Habenicht UF; Neumann F; el Etreby MF
    Acta Urol Belg; 1991; 59(4):1-10. PubMed ID: 1840231
    [No Abstract]   [Full Text] [Related]  

  • 25. [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
    Lopez S; Simon JM; Mazeron JJ
    Bull Cancer; 2009 Mar; 96(3):261-70. PubMed ID: 19318304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
    Koutsilieris M; Dimopoulos T; Milathianakis C; Bogdanos J; Karamanolakis D; Pissimissis N; Halapas A; Lembessis P; Papaioannou A; Sourla A
    BJU Int; 2007 Jul; 100 Suppl 2():60-2. PubMed ID: 17594363
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume.
    Stone NN; Stock RG
    J Urol; 2007 Mar; 177(3):925-8. PubMed ID: 17296377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy.
    Pinkawa M; Fischedick K; Piroth MD; Gagel B; Borchers H; Jakse G; Eble MJ
    Urology; 2007 Jan; 69(1):129-33. PubMed ID: 17270634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume.
    Petit JH; Gluck C; Kiger WS; Laury Henry D; Karasiewicz C; Talcott JA; Berg S; Holupka EJ; Kaplan ID
    Brachytherapy; 2007; 6(4):267-71. PubMed ID: 17959423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormone agonists and antagonists in the treatment of hormone sensitive breast and prostate cancer.
    Nicholson RI; Walker KJ; Davies P
    Cancer Surv; 1986; 5(3):463-86. PubMed ID: 3555778
    [No Abstract]   [Full Text] [Related]  

  • 32. [High risk prostate cancer results of one year RT-HT].
    Delaporte V; Muracciole X; Lechevalier E; Bastide C; Cowen D; Rossi D; Coulange C
    Prog Urol; 2005 Dec; 15(6 Suppl 1):1256-61. PubMed ID: 16734214
    [No Abstract]   [Full Text] [Related]  

  • 33. [False multiple coin lesions in prostatic cancer under hormone therapy].
    Kattan J; Court B; Culine S; Droz JP
    Presse Med; 1993 Jun; 22(23):1104. PubMed ID: 8415464
    [No Abstract]   [Full Text] [Related]  

  • 34. Editorial comment.
    Boorjian SA; Blute ML
    Urology; 2011 Apr; 77(4):950-1. PubMed ID: 21477724
    [No Abstract]   [Full Text] [Related]  

  • 35. Advanced prostate cancer. Hormonal treatment.
    de la Haba-Rodríguez J
    Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
    [No Abstract]   [Full Text] [Related]  

  • 36. Degarelix (firmagon) for prostate cancer.
    Med Lett Drugs Ther; 2009 Oct; 51(1323):82-3. PubMed ID: 19838145
    [No Abstract]   [Full Text] [Related]  

  • 37. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?].
    Matveev BP; Bukharkin BV
    Urologiia; 2003; (6):6-10. PubMed ID: 14708235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prostate cancer: at the beginning of a new millennium].
    Tombal B; Van Cangh PJ
    Acta Urol Belg; 2000; 68(2):29-33. PubMed ID: 11098584
    [No Abstract]   [Full Text] [Related]  

  • 39. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?
    Miyamoto H; Messing EM; Chang C
    Nat Clin Pract Oncol; 2005 May; 2(5):236-7. PubMed ID: 16264955
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.